RECRUITING

Topical Treatment for Atopic Dermatitis

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Medication adherence is a poorly studied phenomenon that challenges both patients and physicians. 50% of individuals with chronic disease are not adherent to their medication regimen. Within the United States, non-adherence to medical treatment leads to approximately $100 billion in hospital admission costs. While the issue of adherence is not limited to any particular field of medicine, non-adherence occurs in approximately one-third to one-half of dermatological patients. Non-adherence is of importance as it is a significant cause of treatment failure, resulting in worse quality of life, worse health outcomes, and increased insurance costs.

Official Title

Topical Treatment for Atopic Dermatitis

Quick Facts

Study Start:2024-09-19
Study Completion:2025-10
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06244212

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:9 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of skin dermatitis
  2. * Age \> 9
  3. * Ability to return for a one-week clinical studies follow-up
  4. * Patients who are candidates for treatment with 0.1% triamcinolone ointment (even if they weren't in the study)
  5. * Adult or pediatric patients with active dermatitis who receive dermatologic care at Atrium Health Wake Forest Baptist, Department of Dermatology.
  1. * Patients without the diagnosis of skin dermatitis
  2. * Inability to return for a one week follow up appointment
  3. * Body Surface Area (BSA) affected \<2%

Contacts and Locations

Study Contact

Irma Richardson, MHA
CONTACT
336.716.2903
irichard@wakehealth.edu

Principal Investigator

Steven R Feldman, MD, PhD
PRINCIPAL_INVESTIGATOR
Wake Forest University Health Sciences

Study Locations (Sites)

Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157
United States

Collaborators and Investigators

Sponsor: Wake Forest University Health Sciences

  • Steven R Feldman, MD, PhD, PRINCIPAL_INVESTIGATOR, Wake Forest University Health Sciences

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-09-19
Study Completion Date2025-10

Study Record Updates

Study Start Date2024-09-19
Study Completion Date2025-10

Terms related to this study

Keywords Provided by Researchers

  • Medication adherence
  • topical medications
  • Triamcinolone

Additional Relevant MeSH Terms

  • Atopic Dermatitis